Advertisement

Schizophrenia and Stein–Leventhal syndrome: comorbidity features

  • Naira R. MatevosyanEmail author
Reproductive Medicine

Abstract

Objective

To explore shared pathogenesis between schizophrenia and polycistic ovary syndrome (PCOS).

Methods

Ninety-six studies of schizophrenia and PCOS from a mean sample of 139 women are recruited from PubMed and FASTSTATS for geometrical regression analysis. Parametric and observational properties of both diseases (gene polymorphism, monoamines, gonadal steroids, gonadotropins, thyroid hormones, insulin sensitivity index, hirsute index, oligomenorrhea, anhedonia, asociality, apathy, emotional withdrawal, alogia, poor rapport, stereotypical thinking, hyperkinetic reactions, treatment with valproate) are stochastically distributed in the elliptical area.

Results

Results of both analyses suggest that insulin resistance and elevated testosterone are predictive to comorbidity. These associations are stronger with calculation from elliptical model (r 2 = 0.92) than a traditional regression analysis (r 2 = 0.65).

Conclusions

Insulin resistance and elevated testosterone in women contribute in shared pathogenesis of schizophrenia and PCOS. 3D regression analysis shows greater strength of association with the “criterion” value.

Keywords

3D regression Comorbidity Schizophrenia Stein–Leventhal syndrome Insulin resistance Testosterone 

Notes

Conflict of interest

None declared.

References

  1. 1.
    Agarwal SK, Judd HL, Magoffin DA (1996) A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 81:3686–3691PubMedCrossRefGoogle Scholar
  2. 2.
    Arad M, Weiner I (2010) Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis. Neuropsychopharmacology 35(7):1570–1582PubMedCrossRefGoogle Scholar
  3. 3.
    Barnes RB (1998) The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies. J Endocrinol Invest 21(9):576–579Google Scholar
  4. 4.
    Bassett AS, Hodgkinson K, Chow RWC et al (1998) 22q11 deletion syndrome in adults with schizophrenia. Am J of Med Genet Part B: Neuropsychiatr Genet 81(4):328–337CrossRefGoogle Scholar
  5. 5.
    Baumgartner A, Gräf KJ, Kürten I et al (1988) The hypothalamic-pituitary-thyroid axis in psychiatric patients and healthy subjects. Repeated measurements of thyroxine, free thyroxine, triiodothyronine, free triiodothyronine, and reverse triiodothyronine in patients with major depressive disorder, schizophrenia and healthy subjects. Psychiatry Res 24(3):283–305CrossRefGoogle Scholar
  6. 6.
    Beard AW (1965) Experiences of schizophrenia. Br Med J 1:848–849CrossRefGoogle Scholar
  7. 7.
    Bodén R, Haenni A, Lindström L, Sundström J (2009) Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res 115(203):141–145PubMedCrossRefGoogle Scholar
  8. 8.
    Bowden CL, Singh V (2008) Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand 111(s426):13–20CrossRefGoogle Scholar
  9. 9.
    Brody EB, Man EB (1950) Thyroid function measured by serum precipitable iodine determinations in schizophrenic patients. The Am J of Psychiatr 107:357–359Google Scholar
  10. 10.
    Bruce-Jones W, Zolese G, White P (1993) Polycystic ovary syndrome and psychiatric morbidity. J Psychosom Obstet Gynecol 14(2):111–116CrossRefGoogle Scholar
  11. 11.
    Canuso CM, Goldstein JM, Wojcik J et al (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatr Res 111(1):11–20CrossRefGoogle Scholar
  12. 12.
    Campbell M, Fish B, David R et al (2005) Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Dev Disord 2(4):343–358CrossRefGoogle Scholar
  13. 13.
    Carney CP, Jones L, Woolson RF (2007) Medical comorbidity in women and men with schizophrenia. J Gen Intern Med 21(11):1133–1137CrossRefGoogle Scholar
  14. 14.
    Chua WL- LC, de Santiago AI, Kulkarni J, et al. Estrogens for schizophrenia. Cochrane Database of Systematic Reviews, 2010; Issue 1Google Scholar
  15. 15.
    Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane Database Systematic Reviews, 2005; (4):CD004719Google Scholar
  16. 16.
    Chun-Sen H, Chien-Hua W, Wan-Chun C et al (2010) Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 27(5):300–306PubMedCrossRefGoogle Scholar
  17. 17.
    Ciotta L, De Leo V, Galvani F et al (1999) Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. Hum Reprod 14(12):2951–2958PubMedCrossRefGoogle Scholar
  18. 18.
    Cohen RZ, Seeman MV, Gotowiec A et al (1999) Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatr 156:1059–1065PubMedGoogle Scholar
  19. 19.
    Cooper NJ, Jones DR, Sutton AJ (2005) The use of systematic reviews when designing studies. Clin Trials 2:260–264PubMedCrossRefGoogle Scholar
  20. 20.
    Cope SL (1965) Hormone reviews. Br Med J 1:849CrossRefGoogle Scholar
  21. 21.
    Correll C, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Child Adolesc Psychiatr 45(7):771–791CrossRefGoogle Scholar
  22. 22.
    Dasgupta A, Singh OP, Rout JK et al (2010) Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatr 34(7):1202–1207CrossRefGoogle Scholar
  23. 23.
    DeLisi LE, Smith AB, Razi K et al (2000) Investigation of a candidate gene for schizophrenia on Xq13 previously associated with mental retardation and hypothyroidism. Am J Med Genet 96(3):398–403PubMedCrossRefGoogle Scholar
  24. 24.
    Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18(6):774–800PubMedCrossRefGoogle Scholar
  25. 25.
    Eaton WW, Byrne M, Ewald H et al (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish National Registers. Am J Psychiatr 163:521–528PubMedCrossRefGoogle Scholar
  26. 26.
    Eldar-Geval T, Shoham M, Rösler A et al (2007) Subclinical hypothyroidism in infertile women: the importance of continuous monitoring and the role of the thyrotropin-releasing hormone stimulation test. Gynecol Endocrinol 23(6):332–337CrossRefGoogle Scholar
  27. 27.
    Elsenbruch S, Hahn S, Kowalsky D et al (2008) Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:5801–5807CrossRefGoogle Scholar
  28. 28.
    Ernst CL, Goldberg JF (2002) The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatr 63(Suppl4):42–55Google Scholar
  29. 29.
    Farrell K, Antoni MH (2010) Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: bio-behavioral mechanisms and interventions. Fertil Steril 94(5):1565–1574PubMedCrossRefGoogle Scholar
  30. 30.
    Feldman D, Goldberg JF (2002) A preliminary study of the relationship between Clozapine-induced weight gain and menstrual irregularities in schizophrenic, schizoaffective, and bipolar women. Ann Clin Psychiatr Clin Psychol-Adult 14(1):17–21Google Scholar
  31. 31.
    Fisun A (2010) Female-specific health problems in mental patients. Curr Opin Psychiatr 23(4):378–382CrossRefGoogle Scholar
  32. 32.
    Fitko R, Jan Kucharski J, Szlezyngier B (1995) The importance of thyroid hormone in experimental ovarian cyst formation in gilts. Animal Reprod Sci 39(2):159–168CrossRefGoogle Scholar
  33. 33.
    de França Neto AH, Rogatto S, Do Amorim MM et al (2010) Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol 26(10):708–711PubMedCrossRefGoogle Scholar
  34. 34.
    Freeman R, Pollack R, Rosenbloom E (2010) Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 3:1–24Google Scholar
  35. 35.
    Gerli S, Papaleo E, Ferrari A, Di Renzo GC (2007) Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 11:347–354PubMedGoogle Scholar
  36. 36.
    Ghaziuddin M (1988) Polycystic ovary disease, manic-depressive illness and mental retardation. J Intellect Disabil Res 33(4):335–338CrossRefGoogle Scholar
  37. 37.
    Ghosh S, Kabir SN, Pakrashi A, et al (1993) Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res Pediatr 39(1–2):61–66Google Scholar
  38. 38.
    González A, Sáez ME, Aragón MJ et al (2006) Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome. Hum Reprod 21(4):943–951PubMedCrossRefGoogle Scholar
  39. 39.
    Goodarzi MO (2007) The Polycystic ovary syndrome: current concepts on pathogenesis and clinical care. B chapter Endocr Updates 27:29–42CrossRefGoogle Scholar
  40. 40.
    Grigoriadis S, Seeman MV (2002) The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatr 47:437–442Google Scholar
  41. 41.
    Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5(5):539–551PubMedCrossRefGoogle Scholar
  42. 42.
    Hanzu FA, Radian S, Attaoua R et al (2010) Association of insulin receptor genetic variants with polycystic ovary syndrome in a population of women from Central Europe. Fertil Steril 94(6):2389–2392Google Scholar
  43. 43.
    Hendrick V, Altshuler LL, Burt VK (1996) Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 4(4):200–2007PubMedCrossRefGoogle Scholar
  44. 44.
    Herken H, Erdal M, Aydin N et al (2009) The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 28(10):515–519PubMedCrossRefGoogle Scholar
  45. 45.
    Hirschhorn JN, Lohmueller KB, Kirk Byrne E et al (2002) A comprehensive review of genetic association studies. Genet Med 4(2):45–61PubMedCrossRefGoogle Scholar
  46. 46.
    Hoff AL, Kremen WS, Wieneke MH et al (2001) Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 158:1134–1139PubMedCrossRefGoogle Scholar
  47. 47.
    Hoffer A (2001) Thyroid and Schizophrenia. J Orthomol Med 16(4):205–212Google Scholar
  48. 48.
    Huang MC, Lu ML, Tsai CJ et al (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120(4):274–280PubMedCrossRefGoogle Scholar
  49. 49.
    Indhavivadhana S, Wongwananuruk T, Rattanachaiyanont M et al (2010) Prevalence of metabolic syndrome in reproductive-aged polycystic ovary syndrome Thai women. J Med Assoc Thail 93(6):653–660Google Scholar
  50. 50.
    Janssen OE, Mehlmauer N, Hahn S et al (2004) High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 150(3):363–369PubMedCrossRefGoogle Scholar
  51. 51.
    Johnstone EC, Owens DG, Crow TJ et al (1986) Hypothyroidism as a correlate of lateral ventricular enlargement in manic-depressive and neurotic illness. British J Psychiatry 148:317–321CrossRefGoogle Scholar
  52. 52.
    Joffe H, Cohen LS, Suppesb T et al (2006) Longitudinal follow-up of reproductive and metabolic features of Valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 60(12):1378–1381PubMedCrossRefGoogle Scholar
  53. 53.
    Joffe H, Hall JE, Cohen LS et al (2003) A putative relationship between Valproic Acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 11(2):99–108PubMedCrossRefGoogle Scholar
  54. 54.
    Joffe H, Hayes FJ (2008) Menstrual cycle dysfunction associated with neurological and psychiatric disorders. Their treatment in adolescents. Ann N Y Acad Sci 1135:219–229 (Issue The Menstrual Cycle and Adolescents)PubMedCrossRefGoogle Scholar
  55. 55.
    Kelly DL, Conley RR (2005) Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 66(1):80–84PubMedCrossRefGoogle Scholar
  56. 56.
    Ko YH, Joe SH, Cho W et al (2006) Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53(4):169–175PubMedCrossRefGoogle Scholar
  57. 57.
    Kopala LC, Lewine R, Good KP et al (1997) Clinical features of schizophrenia in a woman with hyperandrogenism. J Psychiatry Neurosci 22(1):56–60PubMedGoogle Scholar
  58. 58.
    Koponen HJ, Hakko HH, Saari KM et al (2010) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J biol Psychiatry 11(2Pt2):262–267PubMedCrossRefGoogle Scholar
  59. 59.
    Kulkarni J (2009) Oestrogen–a new treatment approach for schizophrenia? Med J Aust 190(4 Suppl):S37–38PubMedGoogle Scholar
  60. 60.
    Kulkarni J (2010) Special issues in managing long-term mental illness in women. Int Rev Psychiatry 22(2):183–190PubMedCrossRefGoogle Scholar
  61. 61.
    Kulkarni J, Riedel A, de Castella AR et al (2010) Estrogen—a potential treatment for schizophrenia. Schizophr Res 48(1):137–144CrossRefGoogle Scholar
  62. 62.
    Strauss LegroRS, III JF (2001) Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78(3):569–576Google Scholar
  63. 63.
    Lindley SE, Schröder CM, O`Hara R.(2008) Insulin resistance syndrome and neuropsychiatric disease Informa pp. 49-53Google Scholar
  64. 64.
    Mackin P, Ruttledge S. Physical comorbidity in bipolar disorder. Med Psychiatr Ser 2007/35; pp 391-394Google Scholar
  65. 65.
    Mantel N (1963) Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58(303):690–691Google Scholar
  66. 66.
    Martinos A, Rinieris P, Souvatzoglou A et al (1986) Effects of six weeks’ neuroleptic treatment on the pituitary-thyroid axis in schizophrenic patients. Biol Psychiatry 16:2–3Google Scholar
  67. 67.
    Matsunaga H, Sarai M (1993) Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Psychiatry Clin Neurosci 47(4):825–842CrossRefGoogle Scholar
  68. 68.
    Nestler JE, Jakubowicz DJ (1997) Lean women with PCOS respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 82(12):4075–4079PubMedCrossRefGoogle Scholar
  69. 69.
    Normand ST, Jou KH (2002) Sample size considerations in observational health care quality studies. Stat Med 21:331–345PubMedCrossRefGoogle Scholar
  70. 70.
    Oud MJ, Meyboom-de Jong B (2009) Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 9(10):32CrossRefGoogle Scholar
  71. 71.
    Padmavati R (2010) Metabolic syndrome in mental disorders. Indian J Med Res 131:11–13PubMedGoogle Scholar
  72. 72.
    Pantasri T, Vutyavanich T, Sreshthaputra O et al (2010) Metabolic syndrome and insulin resistance in Thai women with polycystic ovary syndrome. J Med Assoc Thail 93(4):406–412Google Scholar
  73. 73.
    Pethö B, Karczag I, Czeizel A (1982) Familially accumulated schizophrenia (folie à cinq) in association with Stein–Leventhal syndrome. Psychiatria Clinica (Basel) 15(4):206–211Google Scholar
  74. 74.
    Pethö B, Karczag I, Czeizel E (1981) Stein-Leventhal syndrome associated with cumulative familial schizophrenia (folie à cinq). Orv Hetil 122(48):2965–2966PubMedGoogle Scholar
  75. 75.
    Philibert RA, Sandhu HK, Hutton AM et al (2001) Population-based association analyses of the HOPA 12bp polymorphism for schizophrenia and hypothyroidism. Am J Med Genet Part B Neuropsychiatr Genet 105(1):130–134CrossRefGoogle Scholar
  76. 76.
    Prentice R (1976) Use of the logistic model in retrospective studies. Biometrics 32(3):599–606PubMedCrossRefGoogle Scholar
  77. 77.
    Rao ML, Kölsch H (2003) Effects of estrogen on brain development and neuroprotection–implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28(Suppl 2):83–96PubMedCrossRefGoogle Scholar
  78. 78.
    Rasgon NL.(2001) Investigating polycystic ovary syndrome in women with bipolar disorder. Psychiatr Times 18(5)Google Scholar
  79. 79.
    de Resende LO, dos Reis RM, Ferriani RA et al (2010) Concentration of steroid hormones in the follicular fluid of mature and immature ovarian follicles of patients with polycystic ovary syndrome submitted to in vitro fertilization. Ravista Brasileira de Gynecologia e Obstetr 32(9):447–453CrossRefGoogle Scholar
  80. 80.
    Rheingold JC (1939) Autonomic integration in schizophrenia. Autonomic status determined statistically, the thyroid factor, and a possible thyroid-hypothalamus mechanism. Psychosom Med 1:397–413Google Scholar
  81. 81.
    Riecher-Rössler A.(2005) Estrogens and schizophrenia. Estrogen Effects in Psychiatric Disorders, pp. 31-52Google Scholar
  82. 82.
    Riecher-Rössler A, Häfner H, Stumbaum M et al (1994) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20(1):203–214PubMedGoogle Scholar
  83. 83.
    Roepke S, Ziegenhorn A, Kronsbein J et al (2010) Incidence of polycystic ovaries and androgen serum levels in women with borderline personality disorder. J Psychiatr Res 44(13):847–852PubMedCrossRefGoogle Scholar
  84. 84.
    Ryan WG, Roddam RF, Grizzle WE (1994) Thyroid function screening in newly admitted psychiatric inpatients. Ann Clin Psychiatry 6(1):7–12PubMedCrossRefGoogle Scholar
  85. 85.
    Sandhu HK, Sarkar M, Turner BM et al (2003) Polymorphism analysis of HOPA: a candidate gene for schizophrenia. Am J Med Genet 123B(1):33–38PubMedCrossRefGoogle Scholar
  86. 86.
    Seeman MV, Lang M (1990) The role of estrogens in schizophrenia gender differences. Schizophr Bull 16(2):185–194PubMedGoogle Scholar
  87. 87.
    Shikaeva FV, Efimenko NF (1994) Hormonal-mediator interrelationships in polycystic ovary syndrome. Problemi Endocrinologii 40(4):33–35Google Scholar
  88. 88.
    Simson GM, Cranswick EH, Blair ChB (1963) Thyroid indeces in chronic schizophrenia. Nerv Ment Dis 137(6):582–590CrossRefGoogle Scholar
  89. 89.
    Smirnova LK, Zorenko TI ((1993)) Thyroid functional activity in schizophrenic patients with aggressive sexual behavior. Zhurnal Nevrologi I Psikhiatrii Imeni S. S. Korsakova 93(4):68–70Google Scholar
  90. 90.
    Sonino N, Peruzzi P (2009) A psychoneuroendocrinology service. Psychother Psychosom 78(6):346–351PubMedCrossRefGoogle Scholar
  91. 91.
    Sridhar GR, Nagamani G (1993) Hypothyroidism presenting with polycystic ovary syndrome. J Assoc Physicians-India 41(2):88–90PubMedGoogle Scholar
  92. 92.
    Steiner J, Walter M, Guest P et al (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15(1):3–4PubMedCrossRefGoogle Scholar
  93. 93.
    Sundararaman PG, Shweta, Sridhar GR (2008) Psychosocial aspects of women with polycystic ovary syndrome from South India. J Assoc Physicians India 56: 945–948Google Scholar
  94. 94.
    Sutton AJ, Abrams KR, Lambert PC, et al. Meta-analysis in practice: a critical review of available software. Biostatistics; In: Meta-Analysis in Medicine and Health Policy, 2000. New York, Marcel DekkerGoogle Scholar
  95. 95.
    Takeuchi T, Tsutsumi O, Taketani Y (2008) Abnormal response of insulin to glucose loading and assessment of insulin resistance in non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol 24(7):385–391PubMedCrossRefGoogle Scholar
  96. 96.
    Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8(1):41PubMedCrossRefGoogle Scholar
  97. 97.
    Verma SK, Subramaniam M, Liew A, Poon LY (2009) Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 70(7):997–1000PubMedCrossRefGoogle Scholar
  98. 98.
    Vicennati V, Gambineri A, Calzoni F et al (1998) Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47(8):988–992PubMedCrossRefGoogle Scholar
  99. 99.
    Vuguin PM (2010) Interventional studies for polycystic ovarian syndrome in children and adolescents. Pediatr Health 4(1):59–73CrossRefGoogle Scholar
  100. 100.
    Wagner KD, Kowatch RA.(2001) Child and adolescent bipolar disorder: focus on differential diagnosis and management. A Monograph of Continuing Medical Education Credit, ILGoogle Scholar
  101. 101.
    Weber NS, Cowan DN, Millikan AM, Niebuhr DW (2009) Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv 60(8):1059–1067PubMedCrossRefGoogle Scholar
  102. 102.
    West GR (1986) A stochastic analysis of an input-output model. Econometrica 54(2):363–374CrossRefGoogle Scholar
  103. 103.
    Wheeler CJ, Keye WR, Peterson CM. (2010) Polycystic ovary syndrome. Reproductive Endocrinology and Infertility, Part 2, pp 147-182Google Scholar
  104. 104.
    Wilk AI, Jensen NM, Havighurst TC (1997) Meta-analysis of randomized control trials addressing brief interventions. J Gen Intern Med 12(5):274–283PubMedCrossRefGoogle Scholar
  105. 105.
    Yamashita Y, Kawamura T, Rumi Fujikawa R et al (2006) Regression of both pituitary and ovarian cysts after administration of Thyroid hormone in a case of primary hypothyroidism. Intern Med 40(8):751–755CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Alumna of the Open Medical InsituteSalzburgAustria
  2. 2.Emory UniversityAtlantaUSA

Personalised recommendations